BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28757678)

  • 1. MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.
    Mozzoni P; Ampollini L; Goldoni M; Alinovi R; Tiseo M; Gnetti L; Carbognani P; Rusca M; Mutti A; Percesepe A; Corradi M
    Dis Markers; 2017; 2017():9645940. PubMed ID: 28757678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
    Kishimoto T; Fujimoto N; Ebara T; Omori T; Oguri T; Niimi A; Yokoyama T; Kato M; Usami I; Nishio M; Yoshikawa K; Tokuyama T; Tamura M; Yokoyama Y; Tsuboi K; Matsuo Y; Xu J; Takahashi S; Abdelgied M; Alexander WT; Alexander DB; Tsuda H
    BMC Cancer; 2019 Dec; 19(1):1204. PubMed ID: 31823764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.
    Santarelli L; Strafella E; Staffolani S; Amati M; Emanuelli M; Sartini D; Pozzi V; Carbonari D; Bracci M; Pignotti E; Mazzanti P; Sabbatini A; Ranaldi R; Gasparini S; Neuzil J; Tomasetti M
    PLoS One; 2011 Apr; 6(4):e18232. PubMed ID: 21483773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
    Tabata C; Shibata E; Tabata R; Kanemura S; Mikami K; Nogi Y; Masachika E; Nishizaki T; Nakano T
    BMC Cancer; 2013 Apr; 13():205. PubMed ID: 23617783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
    Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
    J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.
    Jiang Z; Ying S; Shen W; He X; Chen J; Xia H; Yu M; Xiao Y; Feng L; Zhu L; Ju L; Guo X; Zhang Y; Shen JW; Tong Y; Zhang X; Lou J
    Dis Markers; 2017; 2017():1725354. PubMed ID: 29200597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
    Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
    Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma.
    Matboli M; Shafei AE; Ali MA; Gaber AI; Galal A; Tarek O; Marei M; Khairy E; El-Khazragy N; Anber N; Abdel-Rahman O
    J Cell Biochem; 2019 Mar; 120(3):3203-3211. PubMed ID: 30362153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
    Matboli M; Shafei AE; Azazy AE; Reda M; El-Khazragy N; Nagy AA; Ali MA; Sobhi M; Abdel-Rahman O
    Biomark Med; 2018 Feb; 12(2):129-139. PubMed ID: 29338319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
    Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
    J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
    Kim K; Ko Y; Oh H; Ha M; Kang J; Kwon EJ; Kang JW; Kim Y; Heo HJ; Kim G; Kim JW; Kim YH
    J Toxicol Environ Health A; 2020 Feb; 83(3):126-134. PubMed ID: 32114955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
    J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
    Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.